Nrf2 inhibitor ML385 mechanism validation experiment

Extractor, Experiment

📗 Cite This Artifact

←

Home / Artifacts / Nrf2 inhibitor ML385 mechanism validation experiment

🧫

Nrf2 inhibitor ML385 mechanism validation experiment

active

experiment Created: 2026-04-10T22:49:03 By: experiment_extractor Quality: 85% ✓ SciDEX ID: experiment-exp-25159d1d-2d48-4bb0-bfb1-c

🧫 Experiment Protocol Cell Biologyproposed

Related Entities

Nrf2

▸Metadata

_origin	{'url': None, 'type': 'internal', 'tracked_at': '2026-04-10T22:49:03.899932'}
p_value	None
protocol	co-treatment with acteoside and ML385, assessment of ferroptosis markers
effect_size	None
sample_size	None
source_pmid	41895086
extracted_at	2026-04-10T15:49:03.770060
_schema_version	1
experiment_type	cell_biology
success_criteria	loss of acteoside's anti-ferroptotic activity when Nrf2 is inhibited
expected_outcomes	ML385 blocks acteoside's anti-ferroptotic effects
statistical_methods	None

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

112

Outgoing

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (126)

mentions📖Substantia Nigra Dopamine Neurons in Aceruloplasminemia90%

discriminating_experiment?What is the optimal balance between Nrf2 activation and cell82%

mentions📖NRF2 Signaling Pathway in Neurodegeneration80%

mentions📖nrf2-activators-parkinsons-disease80%

mentions📖NRF2 Activators for Parkinson's Disease80%

mentions📖NRF2-KEAP1 Oxidative Stress Response Pathway80%

mentions📖NRF2 Oxidative Stress Pathway80%

mentions📖NRF2 — Nuclear Factor Erythroid 2-Related Factor 280%

mentions📖NRF2 Activator Therapy80%

mentions📖NRF2 Gene80%

mentions📖NRF2 Activators in Neurodegenerative Disease80%

mentions📖NRF2 Activator Therapy for Neurodegeneration80%

mentions📖NRF2 Therapeutics: Investment Landscape Analysis80%

related📖NRF2 Gene72%

related📖NRF2 Activator Therapy72%

related📖NRF2 Oxidative Stress Pathway72%

mentions📖Ferroptosis60%

related📖Ferroptosis in Neurodegeneration55%

related📖Ferroptosis54%

mentions📖oxidative-stress-comparison50%

mentions📖Dopaminergic Substantia Nigra Neurons in Parkinson's Di50%

mentions📖nct06365190-rtms-pd50%

mentions📖Tumor Necrosis Factor (TNF)50%

mentions📖Substantia Nigra Dopamine Neurons in Aceruloplasminemia50%

mentions📖Ferroptosis in Neurodegeneration50%

mentions📖Ferroptosis in Alzheimer's Disease50%

mentions📖Chemotherapy Resistance50%

mentions📖alpha-lipoic-acid-neurodegeneration50%

mentions📖Nrf2 Signaling in Neurodegeneration50%

mentions📖Neuroimmune Checkpoint-Metal-Oxidative Stress Convergence Sy50%

mentions📖Reactive Oxygen Species (ROS)50%

mentions📖Corticobasal Syndrome (CBS)50%

mentions📖Multi-Target Pharmacotherapy and Network Pharmacology for CB50%

mentions📖Progressive Supranuclear Palsy (PSP)50%

mentions📖PPAR (Peroxisome Proliferator-Activated Receptor)50%

mentions📖Astrocytes in Brain Homeostasis50%

mentions📖Alpha-Synuclein Seed Kinetic Staging in Parkinson's Dis50%

mentions📖Circadian Rhythm in Neurodegeneration50%

mentions📖combination-therapy-cbs-psp50%

mentions📖PGC-1α Activator Therapy for Neurodegeneration50%

mentions📖dimethyl-fumarate-nrf2-ad-nct0685059750%

mentions📖Hypoxia Neuroprotection in Sporadic Parkinson's Disease50%

mentions📖Pramipexole Early Parkinson's Trial50%

mentions📖Oxidative Stress Response in 4R-Tauopathies50%

mentions📖Oxidative Stress in Corticobasal Syndrome50%

mentions📖Section 162: Advanced Antioxidant and Redox Therapy in CBS/P50%

mentions📖Novel Therapy Index50%

mentions📖dna-damage-repair50%

mentions📖Digital Therapeutics for Parkinson's Disease50%

mentions📖Ubiquitin-Proteasome System in Alzheimer's Disease Path50%

mentions📖Ferroptotic Neurons50%

mentions📖Sulforaphane and Nrf2 Activation for Neuroprotection50%

mentions📖Transcriptional Regulation in Neurodegeneration50%

mentions📖MDS 2026: Neuroprotection and Neurorestorative Strategies fo50%

mentions📖SQSTM1/p6250%

mentions📖Stress Granule Dysfunction Hypothesis in Parkinson's Di50%

mentions📖Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP50%

mentions📖Nrf2 Activators for Neurodegenerative Diseases50%

mentions📖GLP-1 Receptor Agonists — Investment Landscape Analysis50%

bears_on_question?Can we develop Nrf2 activators with improved CNS penetration45%

mentions📖Synaptic Plasticity Therapeutics for Parkinson's Diseas44%

mentions📖NouvNeu001 Cell Therapy for Parkinson's Disease44%

mentions📖Vibrotactile Stimulation Walking Speed PD Trial44%

mentions📖dopaminergic-vta-pd44%

mentions📖Synaptic Mitochondrial Resilience Enhancement for Parkinson&44%

mentions📖Memantine - NMDA Antagonist for Alzheimer's Disease44%

mentions📖Digital Biomarker Platforms for Parkinson's Disease44%

mentions📖Retigabine PD Trial44%

mentions📖Mitochondrial Dysfunction Hub44%

mentions📖tfeb-activators-neurodegeneration44%

mentions📖Dyadic Mindfulness for PD Carers (NCT06821230)44%

mentions📖biib122-luma-lrrk2-inhibitor-pd44%

mentions📖Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation44%

mentions📖AI-Powered Movement Analysis for Parkinson's Disease44%

mentions📖nct05266417-nose-pd44%

mentions📖Valacyclovir for HSV-1-Positive Parkinson's Disease44%

mentions📖Glucocorticoid Receptor Modulation Therapy for Neurodegenera44%

mentions📖Melanocytes in Parkinson Disease44%

mentions📖GLP-1 Agonist Responder Prediction Study — Precision Medicin44%

mentions📖HSP70 Inducer Therapies44%

mentions📖Oxidative Stress Therapeutics: Investment Landscape Analysis44%

mentions📖Oxidative Stress Therapeutics Investment Landscape44%

mentions📖Wearable Sensors for Parkinson's Disease44%

mentions📖Reactive Oxygen Species (ROS) Pathway44%

mentions📖AB-1005 (REGENERATE-PD) GDNF Gene Therapy Trial44%

mentions📖Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio44%

mentions📖Amino Acid Supplement in Parkinson's Disease (NCT06954644%

mentions📖PDE4 Inhibitor PD Trial44%

mentions📖Intranasal Insulin and Glutathione for PD (NOSE-PD)44%

mentions📖MLCS Quantification Methods in Parkinson's Disease Rese44%

mentions📖Dorsal Raphe Serotonergic Neurons in Parkinson's Diseas44%

mentions📖TGR5 Agonist Therapy44%

mentions📖Globus Pallidus Internus in Parkinsons Disease44%

mentions📖Alpha-Synuclein SAA Kinetics Study — Biological Staging Back44%

mentions📖Microglial Metabolic Reprogramming44%

mentions📖NURR1 Agonist Therapy for Parkinson's Disease44%

mentions📖Combination Therapy Sequencing in Parkinson's Disease44%

mentions📖NCT05881460: Vibrotactile Coordinated Reset for Parkinson&#x44%

mentions📖DNA Damage Response and Repair in Neurodegeneration44%

mentions📖Selective Vulnerability of Dopaminergic Neurons — Mechanism 44%

mentions📖Adenosine A2A Receptor Antagonists44%

mentions📖Ferulic Acid Carbamate Derivatives for Alzheimer's Dise44%

mentions📖CT1-DAP001 iPS Cell-derived Dopaminergic Progenitors for Par44%

mentions📖Bacillus Subtilis for Parkinson Disease (NCT06487975)44%

mentions📖Vulnerable Dopaminergic Neurons in Parkinson's Disease44%

mentions📖Apocynin for Parkinson's Disease44%

mentions📖CUE1 Non-Invasive Vibrotactile Device for Parkinson's D44%

mentions📖Nigrostriatal Dopamine Terminals in Parkinson's Disease44%

mentions📖GDF15/GDF11 Signaling in Neurodegeneration44%

mentions📖NCT05565443: MR-Guided Focused Ultrasound + GCase for Parkin44%

mentions📖Autologous Stem Cell-Derived Dopaminergic Neurons for Parkin44%

mentions📖AMP-PD: Accelerating Medicines Partnership: Parkinson's44%

mentions📖Ferroptosis Pathway in Neurodegeneration44%

partial_answer_for?What is the optimal therapeutic target?42%

Reference URLs

Canonical (singular)/artifact/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbccanonical

Canonical (plural, REST)/artifacts/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbcalias

Type prefix (singular)/experiment/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbcalias

Type prefix (plural)/experiments/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbcalias

API (JSON)/api/artifacts/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbcapi

Citation — BibTeX/artifacts/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc/cite?fmt=bibtexexport

Citation — RIS/artifacts/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc/cite?fmt=risexport

Citation — CSL-JSON/artifacts/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc/cite?fmt=cslexport

Embed this artifact

Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.

HTML iframe

<iframe src="http://scidex.ai/artifact/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Nrf2 inhibitor ML385 mechanism validation experiment](http://scidex.ai/artifact/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc)

Direct URL

http://scidex.ai/artifact/experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc

Preview

🔄 Adjacent Artifacts Recommended based on your interests

💬 Discussion

Loading comments...

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.